Trend
DailyUptrend (starting)
4 hourStrong Bullish
1 hourStrong Bearish
15 minStrong Bearish
5 minSymmetric Triangle
Daily trend turns down below $18.39
Key levels
Resistance$20.25
Resistance$18.39
Support$16.86
Support$14.45
Latest news & SEC filings
AnalystDeutsche Bank trims its ACADIA Pharmaceuticals valuation to $27
ProductAcadia Pharmaceuticals to Share Remlifanserin Findings at 2026 CTAD Meeting
All ACAD news →Acadia Pharmaceuticals is a biopharmaceutical company that develops and sells therapies for disorders of the brain and nervous system as well as uncommon genetic conditions. Its marketed drugs are NUPLAZID (pimavanserin), used for hallucinations and delusions in Parkinson's disease psychosis, and DAYBUE (trofinetide), used for Rett syndrome. It also has earlier-stage candidates for Alzheimer's disease psychosis, Lewy body dementia psychosis, major depressive disorder, essential tremor, and Huntington's disease. The company is headquartered in San Diego, California, with operations in Princeton, New Jersey and a European base in Zug, Switzerland, and sells mainly across North America and Israel.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
SEPT Low Target
$23.00
SEPT Mid Target
$33.00
SEPT High Target
$36.00
Analyst Consensus
$33.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ACAD.
Start Free Trial →Valuation Verdict
OVERVALUED
Methods Used
P/E Forward, P/B, PEG, Analyst Consensus
Fair Value
$26.06
56
Moat Score
NARROW
5/9
Piotroski Score
6.1
Altman Z-Score
Insider Signal
SELLING
0 buys / 15 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Schneyer Mark C. | officer | Sale | 3,321 | $69K | Oct 30, 2026 |
| Schneyer Mark C. | officer | Buy | 6,815 | - | Oct 15, 2026 |
| BAKER BROS. ADVISORS LP | director 10% owner | Buy | 18,622 | - | May 29, 2026 |
| Kihara James | officer | Sale | 5,401 | $114K | May 26, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
11.9%
3yr Revenue CAGR
27.5%
EPS Growth YoY
69.12%
FCF Growth YoY
-33.1%
Revenue Trend
STRONG
SEPT Investing tracks real-time dark pool institutional trades for ACAD, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:08 | $18.37 | 1,661 | $$31K | BUY |
| 21:00:08 | $18.37 | 8,639 | $$159K | BUY |
| 21:00:08 | $18.37 | 1,641 | $$30K | BUY |
| 21:00:08 | $18.37 | 9,761 | $$179K | BUY |
| 21:00:08 | $18.37 | 2,057 | $$38K | BUY |
5 dark pool trades shown · $$436K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT Investing provides real-time options flow tracking for ACAD, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $25 | Jun 17 | 218 | $$130 | 1 | SWEEP |
| PUT | $16 | Dec 18 | 37 | $$340 | 17 | SWEEP |
| CALL | $20 | Mar 19 | 128 | $$150 | 1 | SWEEP |
3 options trades shown · 67% calls
Unusual activity, GEX levels, max pain, and dealer positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for ACADIA PHARMACEUTICALS INC (ACAD) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ACADIA PHARMACEUTICALS INC (ACAD) is at $18.13, down 1.31% (-$0.24) at the Nov 12, 2026 close.
Latest ACAD news — Nov 11, 2026: Deutsche Bank trims its ACADIA Pharmaceuticals valuation to $27 · Nov 9, 2026: Acadia Pharmaceuticals to Share Remlifanserin Findings at 2026 CTAD Meeting
The average analyst price target for ACAD is $33.00, ranging from $23 to $36, based on 14 analysts.
Analyst ratings for ACAD: 0 Buy, 24 Hold, 1 Sell — consensus Hold.
ACAD last reported on Nov 4, 2026: EPS $0.31 vs $0.20 expected — a beat of 55.6%.
ACAD trades at a P/E of 9.6 vs a Healthcare average of 18.5.
ACAD does not currently pay a dividend.
Support: $16.86, $14.45. Resistance: $18.39, $20.25, $21.96.
Insider activity: SELLING, 0 buys and 15 sells in the last 90 days.
Nov 11, 2026: Deutsche Bank trims its ACADIA Pharmaceuticals valuation to $27 · Nov 9, 2026: Acadia Pharmaceuticals to Share Remlifanserin Findings at 2026 CTAD Meeting